Waddell & Reed Financial’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Waddell & Reed Financial’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-100,000	Closed	-$11.5M	–	612
2014 Q4	$11.5M	Buy	100,000 +41,300	+70%	+$5M	0.02%	394
2014 Q3	$9.17M	Sell	58,700 -4,420	-7%	-$641K	0.01%	416
2014 Q2	$7.79M	Sell	63,120 -98,450	-61%	-$10.9M	0.01%	457
2014 Q1	$16.7M	Sell	161,570 -8,260	-5%	-$846K	0.03%	357
2013 Q4	$15.3M	Hold	169,830	–	–	0.02%	354
2013 Q3	$11.4M	Hold	169,830	–	–	0.02%	395
2013 Q2	$11.2M	Buy	+169,830	New	+$9.71M	0.02%	372

Other funds holding SLXP

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Waddell & Reed Financial's SLXP Position: Q1 2015 in Review

Waddell & Reed Financial sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 100,000 shares — an estimated $11.5M sold.

Waddell & Reed Financial first reported a position in SLXP in Q2 2013 and held it in 7 quarters. The position peaked at $16.7M in Q1 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

Waddell & Reed Financial reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
Waddell & Reed Financial sold 100,000 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $11.5M.
Waddell & Reed Financial first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 7 quarters.
Waddell & Reed Financial's SALIX PHARMACEUTICALS LTD DEL position peaked at $16.7M in Q1 2014.
298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on Waddell & Reed Financial's 13F filing for Q1 2015, filed 15 May 2015.